Clinical Trial Update: Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating icatibant for COVID-19 pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Sebastian Videla | Conditions: COVID-19 Pneumonia | Phase 2 | Status: COMPLETED